|
|
|
|
|
|
|
16.07.26 - 14:39
|
CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026 (Business Wire)
|
|
|
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.
A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx's Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone, register here. Upon registering, a dial-in number and unique PIN will be provided.
About CareDx
CareDx is a leading precision medicine diagnostics company advancing care in transplant, specialty oncology, and cell therapy. Through non-invasive longitudinal molecular biomarker testing, digital health, and patient support solutions, CareDx is dedicated to improving patient outcomes. For more information, ...
|
|
|
|
|
01.07.26 - 22:09
|
CareDx Completes Acquisition of Naveris, Extending Leadership into High-Growth Specialty Oncology (Business Wire)
|
|
|
NavDx® is the only Medicare-covered MRD test for HPV-positive Head & Neck and Anal Cancers
Expands CareDx's estimated addressable market to more than $12 billion across transplant, specialty oncology, and cell therapyBRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy today announced the successful completion of its previously announced acquisition of Naveris, following the satisfaction of all closing conditions. The transaction terms were disclosed at the time of announcement in April 2026.
Naveris's lead product, NavDx, is a blood-based test that detects and monitors viral-mediated cancers — including human papillomavirus (HPV)-associated head and neck and anal cancers — from diagnosis through post-treatment molecular residual disease (MRD) surveillance. NavDx is the first and only Medicare-covered assay for HPV-driven head and neck and anal cancer MRD.
Over 130,000 NavDx tests have be...
|
|
|
|
|
|
|
|
|
22.06.26 - 04:12
|
CareDx′s CEO Sells 17K Shares (Fool)
|
|
|
CareDx, a leader in transplant diagnostics, saw a key insider reduce his direct holdings amid a series of scheduled transactions....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.05.26 - 22:06
|
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
|
|
|
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the award of inducement grants.
On April 30, 2026, as an inducement material to acceptance of employment with CareDx, 23 new employees were awarded restricted stock units (RSUs) for an aggregate of 63,856 shares of common stock.
The RSU awards were made pursuant to the Company's 2019 and 2025 Inducement Equity Incentive Plans in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSUs will vest over four years, with 25% of the RSUs vesting on the first anniversary of each employee's vesting commencement date, and 1/16th of the RSUs vesting on each date that is three (3) months thereafter subject to each employee's continued service through each vesting date.
CareDx is providing this information...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
